Prolactinoma Screening: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{CMG}}{{AE}}{{Anmol}} There is insufficient evidence to recommend routine screening for prolactinoma.") |
No edit summary |
||
| Line 2: | Line 2: | ||
{{CMG}}{{AE}}{{Anmol}} | {{CMG}}{{AE}}{{Anmol}} | ||
==Overview== | |||
There is insufficient evidence to recommend routine screening for [[prolactinoma]]. | There is insufficient evidence to recommend routine screening for [[prolactinoma]]. | ||
==Screening== | |||
There is insufficient evidence to recommend routine screening for [[prolactinoma]]. | |||
== References == | |||
{{Reflist|2}} | |||
{{WikiDoc Help Menu}} | |||
[[Category:Disease]] | |||
[[Category:Neuroendocrinology]] | |||
Revision as of 19:15, 21 July 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
There is insufficient evidence to recommend routine screening for prolactinoma.
Screening
There is insufficient evidence to recommend routine screening for prolactinoma.